Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

More articles from Erratum

  • You have access
    Correction to “Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity”
    Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 67; DOI: https://doi.org/10.1124/jpet.121.000821err
  • You have access
    Correction to “A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor ɣ with Excellent Effect on Insulin Resistance and Type 2 Diabetes”
    Journal of Pharmacology and Experimental Therapeutics January 2022, 380 (1) 90-91; DOI: https://doi.org/10.1124/jpet.115.223107err
  • You have access
    Correction to “Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II – Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertensin”
    Journal of Pharmacology and Experimental Therapeutics September 2021, 378 (3) 322; DOI: https://doi.org/10.1124/jpet.121.000525err
  • You have access
    Correction to “Inhibition of Glucose-6-Phosphate Dehydrogenase Activity Attenuates Right Ventricle Pressure and Hypertrophy Elicited by VEGFR Inhibitor + Hypoxia”
    Journal of Pharmacology and Experimental Therapeutics August 2021, 378 (2) 69; DOI: https://doi.org/10.1124/jpet.120.000166err
  • You have access
    Correction to “Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome”
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 368; DOI: https://doi.org/10.1124/jpet.119.262238err
  • You have access
    Correction to “Glutathione S-Transferase P Influences Redox Homeostasis and Response to Drugs that Induce the Unfolded Protein Response in Zebrafish”
    Journal of Pharmacology and Experimental Therapeutics April 2021, 377 (1) 199; DOI: https://doi.org/10.1124/jpet.120.000417err
  • You have access
    Correction to “A Novel Mitochondrial Complex of Aldosterone Synthase, Steroidogenic Acute Regulatory Protein, and Tom22 Synthesizes Aldosterone in the Rat Heart”
    Journal of Pharmacology and Experimental Therapeutics April 2021, 377 (1) 200; DOI: https://doi.org/10.1124/jpet.120.000365err
  • You have access
    Correction to “Specific Lowering of Asymmetric Dimethylarginine by Pharmacological Dimethylarginine Dimethylaminohydrolase Improves Endothelial Function, Reduces Blood Pressure and Ischemia-Reperfusion Injury”
    Journal of Pharmacology and Experimental Therapeutics March 2021, 376 (3) 463; DOI: https://doi.org/10.1124/jpet.120.000212err
  • You have access
    Correction to “Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor”
    Journal of Pharmacology and Experimental Therapeutics January 2021, 376 (1) 147; DOI: https://doi.org/10.1124/jpet.119.261065err
  • You have access
    Correction to “Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2”
    Journal of Pharmacology and Experimental Therapeutics October 2020, 375 (1) 238; DOI: https://doi.org/10.1124/jpet.119.263491err

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 18
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics